Works matching IS 17582652 AND DT 2010 AND VI 13 AND IP Suppl 4

Results: 286

Fracture risk in HIV and the need for guidelines: the Probono-1 Trial.

Published in:

2010

By:

Peters, B.;
Isohanni, H.;
Tillet, S.;
Ibrahim, F.;
Hampson, G.;
Williams, F. M. K.;
Perry, M. E. O.;
Duncan, A.;
Wierzbicki, A.

Publication type:

Abstract

Quantitative ultrasound (QUS) in HIV-infected patients: a reliable and low-cost technique for bone health assessment.

Published in:

2010

By:

Marocco, R.;
Martini, H.;
Belvisi, V.;
Tieghi, T.;
Cesareo, R.;
Del Borgo, C.;
Lichtner, M.;
Mastroianni, C. M.

Publication type:

Abstract

Markers of bone turnover are elevated in patients on antiretrovirals independent of the substance used.

Published in:

2010

By:

Piso, R. J.;
Rothen, M.;
Rothen, J. P.;
Stahl, M.

Publication type:

Abstract

Lack of association between mitochondrial DNA polymorphisms and didexoxynucleoside-induced hyperlactataemia in black-African, HIV-1-infected patients.

Published in:

2010

By:

Arenas-Pinto, A.;
Weller, I.;
Ekong, R.;
Grant, A.;
Karstaedt, A.;
Telisinghe, L.;
Bolhaar, M.;
Charalambous, S.;
Bradman, N.;
Ingram, C.

Publication type:

Abstract

Toxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4-cell decline.

Published in:

2010

By:

de Jong, E.;
Haverkort, M. E.;
Heine, R. ter;
Jansen, R. S.;
Beijnen, J. H.;
van Agtmael, M. A.

Publication type:

Abstract

A case of nodular regenerative hyperplasia in a patient who had been taking didanosine.

Published in:

2010

By:

Jackson, C.;
Fox, R.;
Priest, M.;
Clutterbuck, D.;
Peters, E.

Publication type:

Abstract

Clinical significance of hyperbilirubinemia in the CASTLE study.

Published in:

2010

By:

Uy, J.;
Hu, W.;
Wirtz, V.;
Hosey, T.;
Butcher, D.;
McGrath, D.;
Farajallah, A.

Publication type:

Abstract

Liver fibrosis: concordance analysis between APRI and FIB-4 scores, evolution and predictors in a cohort of HIV patients without HCV and HBV infection.

Published in:

2010

By:

Mendeni, M.;
Focà, E.;
Gotti, D.;
Ladisa, N.;
Quiros-Roldan, E.;
Vavassori, A.;
Castelnuovo, F.;
Carosi, G.;
Angarano, G.;
Torti, C.

Publication type:

Abstract

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients.

Published in:

2010

By:

Macías, J.;
Mallolas, J.;
López-Cortés, L. F.;
Cartón, J. A.;
Domingo, P.;
Moreno, S.;
Iribarren, J. A.;
Neukam, K.;
Rodrigo, A.;
Jiménez-Expósito, M. J.;
Pineda, J. A.

Publication type:

Abstract

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin.

Published in:

2010

By:

Mankhatitham, W.;
Lueangniyomkul, A.;
Manosuthi, W.

Publication type:

Abstract

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug.

Published in:

2010

By:

Billaud, E.;
Lacombe, J. M.;
Abgrall, A.;
Ghosn, J.;
Launay, O.;
Livrozet, J. M.;
Meynard, J. L.;
Pavie, J.;
Costagliola, D.

Publication type:

Abstract

Prevalence of chronic renal failure stage 3 or more in HIV-infected patients in Antwerp: an observational study.

Published in:

2010

By:

Colson, A. W.;
Florence, E.;
Augustijn, H.;
Verpooten, G. A.;
Lynen, L.;
Gheuens, E.

Publication type:

Abstract

Nutritional status in HIV-infected patients using Changi's mini nutritional assessment.

Published in:

2010

By:

Cervero, M.;
Alcázar, V.;
Sanz, R.;
Calle, C. García-La;
Agud, J. L.

Publication type:

Abstract

Metabolic: week 48 comparison of METABOLIK parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir.

Published in:

2010

By:

Overton, T.;
Aberg, J. A.;
Gupta, S.;
Ryan, R.;
Baugh, B.;
De La Rosa, G.

Publication type:

Abstract

Hypertriglyceridemic waist identifies HIV+ men and women at increased cardiometabolic risk.

Published in:

2010

By:

Guaraldi, G.;
Zona, S.;
Orlando, G.;
Carli, F.;
Stentarelli, C.;
Despres, J.;
Ross, R.

Publication type:

Abstract

Mesenteric fat thickness in a group of HIV patients on HAART.

Published in:

2010

By:

Lee, S. S.;
Liu, E.;
To, K. W.

Publication type:

Abstract

The association between metabolic syndrome and the occurrence of nephrolithiasis in HIV-infected patients.

Published in:

2010

By:

Dumitru, I. M.;
Rugina, S.;
Sotila, G.;
Dumitru, E.;
Rugina, C. N.

Publication type:

Abstract

Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia.

Published in:

Journal of the International AIDS Society, 2010, v. 13, n. Suppl 4, p. 1, doi. 10.1186/1758-2652-13-S4-P87

By:

Haverkort, M. E.;
van der Spek, B. W.;
Lips, P. T.;
Slieker, W. A. T.;
Bronsveld, W.

Publication type:

Article

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART).

Published in:

2010

By:

Cassetti, I.;
Etzel, A.;
Madruga, J. V.;
Suleiman, J. M.;
Zhou, Y.;
Rhee, M.;
Warren, D. R.

Publication type:

Abstract

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial).

Published in:

2010

By:

Izzo, I.;
Albini, L.;
Calabresi, A.;
Motta, D.;
Bellagamba, R.;
Fezza, R.;
Narciso, P.;
Sighinolfi, L.;
Maggi, P.;
Focà, E.;
Mendeni, M.;
Manili, L.;
Magoni, M.;
Carosi, G.;
Quiros-Roldan, E.;
Torti, C.

Publication type:

Abstract

Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART.

Published in:

2010

By:

Uglietti, A.;
Gervasoni, C.;
Gabrielli, E.;
Di Giambenedetto, S.;
Cauda, R.;
Esposito, R.;
Grima, P.;
Di Perri, G.;
Maserati, R.;
Galli, M.

Publication type:

Abstract

Kidney tubular function and serum phosphate levels in HIV-1-infected patients treated with tenofovir: preliminary results.

Published in:

2010

By:

Grima, P.;
Zizza, A.;
Calabrese, P.;
Chiavaroli, R.;
Faraone, A.;
Tana, M.;
Sodo, M. R.;
Tundo, P.;
Guido, M.

Publication type:

Abstract

CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years.

Published in:

2010

By:

Podzamczer, D.;
Tiraboschi, J. M.;
Mallolas, J.;
Cárdenes, M. A.;
Casas, E.;
Castro, A.;
Echevarria, S.;
Leal, M.;
de Quirós, J. C. Lopez Bernanldo;
Moreno, S.;
Puig, T.;
Ribera, E.;
Villalonga, C.;
Sirvent, J. L. Gomez;
Heranejos, J. A. Garcia;
Lopez-Aldeguer, J.;
Barrufet, P.;
Force, L.;
Santos, I.;
Sanz, J.

Publication type:

Abstract

Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA.

Published in:

2010

By:

Ryom, L.;
Mocroft, A.;
Reiss, P.;
Ledergerber, B.;
De Wit, S.;
Duiculescu, D.;
Monforte, A. D.;
Murphy, M.;
Lundgren, J. D.;
Kirk, O.

Publication type:

Abstract

Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study.

Published in:

2010

By:

Moyle, G.;
Orkin, C.;
Fisher, M.;
Anderson, J.;
Dhar, J.;
Wang, M. H.;
Ewan, J.

Publication type:

Abstract

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC).

Published in:

2010

By:

Baran, R. W.;
Dietz, B.;
Fredrick, L. M.;
Tian, M.;
Podsadecki, T.

Publication type:

Abstract

Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study).

Published in:

2010

By:

Rodriguez, J. M.;
Delgado, M.;
Viciana, P.;
Lopez-Ruz, M. A.;
Leal, M.;
Alcacer, F.;
Deig, E.;
Antela, A.;
Pedrol, E.;
Moreno, S.

Publication type:

Abstract

Lipodystrophy and metabolic syndrome in Romanian HIV-infected adults.

Published in:

2010

By:

Arbune, M.

Publication type:

Abstract

Altered phosphate metabolism in HIV-1-infected patients: another feature of metabolic syndrome?

Published in:

2010

By:

Grima, P.;
Zizza, A.;
Guido, M.;
Calabrese, P.;
Chiavaroli, R.;
Sodo, M. R.;
Tana, M.;
Tundo, P.

Publication type:

Abstract

Dietician-based approach to lipodystrophic syndrome: role of bioelectrical impedance analysis at week 12.

Published in:

2010

By:

Orofino, G.;
Guastavigna, M.;
Martinoglio, P.;
Penoncelli, D.;
Demarie, D.;
Tettoni, M.;
Desiderato, P.;
Di Frenna, R.;
Zignin, C.

Publication type:

Abstract

Alexithymia, an impairment of emotional cognitive processing, is a candidate risk factor for carotid artery plaque formation in HIV-infected patients.

Published in:

2010

By:

Vadini, F.;
Sozio, F.;
Mazzotta, E.;
Agostinone, C.;
Ursini, T.;
Agostinone, A.;
Placido, G.;
Manzoli, L. M.;
Parruti, G.

Publication type:

Abstract

Adiponectin and leptin levels in HIV-infected patients with lipodystrophy in Southern India.

Published in:

2010

By:

Jacob, S. Mini;
Phoebe, K. Annie;
Hemalatha, R.;
Sivakumar, M. R.;
Ravindran, M. P.;
Natarajan, M. V.

Publication type:

Abstract

Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy.

Published in:

2010

By:

Palacios, R.;
González-Correa, J. A.;
Ruiz, J.;
Nuño, E.;
Márquez, M.;
de la Cruz, J. P.;
Santos, J.

Publication type:

Abstract

Treatment of HIV-2 infection: a retrospective study from a Portuguese center.

Published in:

2010

By:

Marques, N.;
Seixas, D.;
Crespo, P.;
Malcata, L.;
Vaz, J.;
Mota, V.;
Morais, C.;
Oliveira, J.;
Duque, V.;
da Cunha, J. Saraiva;
Meliço-Silvestre, A.

Publication type:

Abstract

Epidemiological description of the demographic and HIV disease characteristics of HIV patients who are in care but not on treatment in Spain.

Published in:

2010

By:

Domingo, P.;
Arazo, P.;
Casado, J. L.;
Castaño, M. A.;
Ferrer, E.;
Goenaga, M. A.;
Granados, R.;
Pulido, F.;
Rodriguez, J.;
Rubio, R.;
Sanz, J.;
Viciana, P.

Publication type:

Abstract

Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir.

Published in:

2010

By:

Garvey, L. J.;
Higgs, C.;
Mohammed, P.;
Nelson, M.;
Winston, A.

Publication type:

Abstract

SUPPORT: 48-week results of fosamprenavir/ ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients.

Published in:

2010

By:

Kumar, P.;
DeJesus, E.;
Huhn, G.;
Sloan, L.;
Garcia, F.;
Small, C.;
Edelstein, H.;
Felizarta, F.;
Hao, R.;
Ha, B.;
Stancil, B.;
Ross, L.;
Oie, K.;
Pappa, K.

Publication type:

Abstract

Higher red blood cell distribution width is associated with a worse virologic and clinical situation in HIV-infected patients.

Published in:

2010

By:

Puerta, S.;
Gallego, M.;
Palacios, R.;
Ruiz, J.;
Nuño, E.;
Márquez, M.;
Santos, J.

Publication type:

Abstract

Nitric oxide protects against HIV gp120 endothelial injury.

Published in:

2010

By:

Fiorucci, S.;
Mencarelli, A.;
Francisci, D.;
Distrutti, E.;
Renga, B.;
Baldelli, F.

Publication type:

Abstract

Prevalence of cardiovascular risk factors in Spanish HIV-1-infected male inmates.

Published in:

2010

By:

Golf, J. P.;
Sala, L.;
Aramburo, J.;
Sardà, P.;
Perez-Alvarez, N.;
Llibre, J. M.

Publication type:

Abstract

Low serum phosphate levels are related to increased cardiovascular risk in HIV-1 infected patients.

Published in:

2010

By:

Grima, P.;
Guido, M.;
Chiavaroli, R.;
Tundo, P.;
Zizza, A.

Publication type:

Abstract

Incidence of ischemic cardiovascular events in the maraviroc clinical development program.

Published in:

2010

By:

Portsmouth, S.;
Burnside, R.;
Lazzarin, A.;
Johnson, M.;
Valdez, H.

Publication type:

Abstract

Cardiovascular risk in patients visiting the Hadassah AIDS Center, Jerusalem.

Published in:

2010

By:

Schulman, S.;
Rotshild, V.;
Pops, K. Olshtein;
Korem, M.;
Israel, S.;
Hauzi, M.;
Maayan, S.

Publication type:

Abstract

Immune impairment and adaptive response in relation to antiretroviral therapy of HIV-infection.

Published in:

2010

By:

Kaminskiy, G. D.;
Pronin, A. J.

Publication type:

Abstract

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients.

Published in:

2010

By:

Avihingsanon, A.;
Apornpong, T.;
Kerr, S. J.;
Ananworanich, J.;
Ruxrungtham, K.

Publication type:

Abstract

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir.

Published in:

2010

By:

Francisci, D.;
Falcinelli, E.;
Belfiori, B.;
Petito, E.;
Mezzasoma, M.;
Baldelli, F.;
Gresele, P.

Publication type:

Abstract

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens.

Published in:

2010

By:

Qaqish, R.;
van Wyk, J.;
King, M. S.

Publication type:

Abstract

British HIV and ageing study. HIV and ageing: older people with HIV, who are they?

Published in:

2010

By:

Allan, S.;
Daly, R. A.;
Yoganathan, Y.;
Barrett, S.;
Joseph, A.;
Tariq, A.;
Saing, C. W.;
Williams, C.;
Lane, C.;
Sikorska, J.

Publication type:

Abstract

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

Published in:

2010

By:

Lazzarin, A.;
Johnson, M.;
Ribera, E.;
Weitner, L.;
Chen, S. S.;
Warren, D. R.

Publication type:

Abstract

Switching to dual therapy with darunavir/ ritonavir and etravirine: a simplification strategy.

Published in:

2010

By:

Tyrer, M.;
Swaden, L.;
Marshall, N. J.;
Johnson, M.

Publication type:

Abstract